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Kaposi’s sarcoma herpesvirus (KSHV), also called human herpesvirus 8 (HHV-8), was 
discovered following the AIDS-epidemic as the causative agent of Kaposi’s sarcoma 
(KS), an angiogenic endothelial tumor of the skin, and of two rare lymphoproliferative 
diseases, primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD). 
Infection by KSHV displays two life cycle phases; latent and lytic replication. In latency, 
the virus stays dormant within the host, expressing only a few genes and no viral particles 
are produced. Latency is the default mode of infection, however, upon appropriate 
induction the virus reactivates to express all of its genes and replicate viral DNA during 
the productive lytic replication, culminating with the release of infectious progeny 
particles and lysis of the host cells. Virus reactivation from latency to the lytic replication 
is an essential step in the KS pathogenesis.  
Upon KSHV infection, endothelial cells (EC) undergo reprogramming towards spindle 
cell, the principal proliferating cell in advanced KS lesions. The transcription factor 
prospero related homeobox gene Prox1 has an important role in mediating the effects 
of KSHV on EC reprogramming, contributing to the KS development. Prox1 is the 
master regulator of lymphatic endothelial cell fate, and its expression is manipulated 
during the KSHV infection. However, the role of Prox1 in the KSHV life cycle and lytic 
reactivation has not been studied.  
To elucidate the role of Prox1 in KSHV reactivation from latency, the effect of ectopic 
expression of Prox1 on the lytic gene and protein expression in both latent and reactivated 
KSHV-infected cells was studied. This led to a significant increase in KSHV lytic gene 
and protein expression, suggesting Prox1 as a positive regulator of KSHV lytic 
replication. Moreover, Prox1 wild-type, but not its DNA-binding deficient mutant, could 
significantly increase the release of infectious virions. To investigate the expression levels 
of Prox1 during KSHV infection, infection kinetics assay was performed, which showed 
an increase in the Prox1 levels during acute infection. Intriguingly, this was followed by 
a progressive decrease in the Prox1 levels as latency was established. In conclusion, the 
focus of this thesis is to investigate the role of Prox1 in KSHV reactivation, and to provide 
a deeper insight into the virus reactivation mechanisms that can be utilized for future 
therapeutic strategies against KSHV-mediated tumorigenesis of KS. 
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1 Introduction  
To date, accumulating evidence suggests that tumor viruses contribute up to 15% of 
human cancers worldwide (Parkin 2006; de Martel et al. 2012). Even though infections 
by oncogenic viruses are common, the development of virus-induced malignancy is a rare 
consequence (Simpson et al. 1996). Complex host-virus interactions and other co-factors, 
both genetic and environmental, contribute to the emergence of cancers associated with 
viral infection (Ensoli and Sturzl 1998; Moore and Chang 2010). It is not evolutionarily 
advantageous for viruses to cause fatal cancer, as they are dependent on their host to 
survive and reproduce. Viral cancers can be considered as accidental manifestations 
resulting from loss of balance between the host and the virus, and just as deletorious to 
both.  
Kaposi’s sarcoma herpesvirus (KSHV) is recognized as one of the human tumor 
viruses, being the causative agent of Kaposi’s sarcoma (KS) (Chang et al. 1994) and two 
rare lymphoproliferative disorders primary effusion lymphoma (PEL) (Cesarman et al. 
1995) and multicentric Castleman’s disease (MCD) (Soulier et al. 1995). KS is an 
angiogenic tumor of endothelial origin, widespread and fatal in patients with acquired 
immunodeficiency syndrome (AIDS) and geographically most prominent in some parts 
of Africa (Martin 2007; Mesri, Cesarman, and Boshoff 2010). However, the therapies 
against KSHV associated malignancies are limited and overall survival of the patients 
remains poor.  
Hallmark of the oncogenic viruses is their prolonged persistence in infected 
individuals, allowing time for the multistep tumorigenesis to develop (Weinberg 1989; 
Moore and Chang 2010). Life-long infection of KSHV is achieved by establishment and 
maintenance of latency, a quiescent dormant state of the virus within the host cells 
(Ballestas, Chatis, and Kaye 1999). Sustained rate of reactivation causes the virus to 
initiate the replication of its own genome and the expression of all the viral genes. This 
lytic replication phase leads to production of new viral particles, and to death of the host 
cell is as virions are released (Renne, Zhong, et al. 1996; Miller et al. 1997; Staskus et al. 
1997). The switch from latency to lytic replication is a crucial step in the pathogenesis of 




generation of virions to disseminate within the host. Furthermore, the lytic phase 
contributes to KS pathogenesis by inducing the production of cellular and virally-encoded 
inflammatory and angiogenic cytokines in the tumor microenvironment (Martin et al. 
1999; Grundhoff and Ganem 2004). Therefore, the virus-host cell interplay has a crucial 
role in KS-induced oncogenesis, and a better understanding of the cellular factors able to 
affect KSHV lytic cycle and tumorigenesis is needed.  
One of the host genes manipulated during KSHV infection is a transcription factor 
Prox1, the master regulator of lymphatic endothelial cell fate (Hong et al. 2004).  KSHV 
infection of endothelial cells (ECs) triggers an aberrant differentiation process that leads 
to a deep reprogramming of those cells as well as to changes in their morphology, growth, 
angiogenic and invasive potential resulting in the characteristic spindle cells, which are 
the predominant proliferating cells in KS lesions and thus considered the KS tumor cells 
(Ganem 2010).  
Substantial understanding of KSHV and its features in tumorigenesis has been 
acquired, even though the virus was discovered as the causative agent of KS only decades 
ago. The goal of developing more potential, rational targets for intervention of the KSHV 
associated diseases can be achieved by studying virus-host interactions and the life cycle 
of KSHV. Classic cancer therapies are generally used to treat KS patients, however, these 
therapeutic agents do not target the virus as latently-infected cells are insensitive to anti-
herpesviral drugs which can target only viruses in the lytic phase, when the viral DNA is 
replicated (Kedes and Ganem 1997; Antman and Chang 2000). Since the fraction of 
viruses reactivating and entering the lytic cycle are susceptible to anti-viral therapy 
(Grundhoff and Ganem 2004), the identification of the cellular players that control 
herpesviral reactivation is of fundamental importance. Understanding the molecular 
mechanisms of KSHV reactivation is of interest to overcome the major obstacle of latency 
for therapies and perhaps in the future achieve eradication of this herpesvirus from its 
host. The role of Prox1 in virus-induced cell reprogramming has been studied (Hong et 
al. 2004; Wang, Trotter, et al. 2004; Yoo et al. 2012) but the role of Prox1 on lytic 




2  Review of the literature 
2.1  Kaposi’s sarcoma 
2.1.1 Pathobiology of Kaposi’s sarcoma 
Kaposi’s sarcoma was first described by a Hungarian dermatologist Moritz Kaposi in 
1872 as “idiopathic multiple pigmented sarcoma of the skin” after discovering patch 
lesions on the skin of 5 of his patients (Sternbach and Varon 1995). At the time naming 
the neoplasm as sarcoma, indicating the similarities to traditional tumors of mesenchymal 
origin, has been reassessed due to unique characteristics of KS (Ganem 2010). In recent 
years, heterogeneity of cell types in various tumors has been noted in contrast to the idea 
of tumors as insular masses of proliferating cancer cells (Hanahan and Weinberg 2011). 
Histologically complex KS neoplasms display remarkable cell type diversity, depending 
on the stage of disease progression (Ganem 2006). 
At the early stages KS appears as a flat patch lesion, without an evident tumor 
mass. In these early lesions, presence of inflammatory cells and dilated EC lined vascular 
spaces in irregular arrangements result in reddish coloration. Abundant 
neovascularization before development of solid tumors distinguishes KS from classical 
cancers that trigger inflammatory and angiogenic responses only at later stages of cancer 
progression. As the abnormal, leaky neovasculature expands through the dermis together 
with erythrocyte extravasation and haemosiderin accumulation, the lesions progress to 
plaque stage with induration and more 
intense red colour (Figure 1). 
Morphologically elongated cells, termed 
spindle cells (SC), arrange around the 
vascular spaces and aggregate forming 
large nodules. At advanced nodular stage, 
KS lesions consist mainly of SCs and of 
slit-like vascular spaces, lacking pericyte 
or smooth muscle coverage found in 
mature blood vessels. Consequently, 
Figure 1. Kaposi’s Sarcoma lesions on the 
skin of an AIDS-patient.  





abnormal vessels are prone to leakage and rupture of blood causing haemorrhage and 
local edema resulting in dark red and violaceus KS nodules. (Gessain and Duprez 2005; 
Grayson and Pantanowitz 2008; Ganem 2010)  
The heterogenic mass lesions are dominated by continuously proliferating 
neoplastic SC, accompanied by infiltrating inflammatory cells such as B and T cells, 
plasma cells, and monocytes, besides the extravasated erythrocytes (Ganem 2010). 
Contribution of inflammatory microenvironment is essential for KS tumorigenesis and 
promotes the establishment of the lesions.  From the inception of KS lesion, proliferation 
of SC, angiogenic perfusion of vasculature, and inflammatory cytokines, all are necessary 
and participate to the disease progression (Ensoli and Sturzl 1998; Ganem 2010; Mesri, 
Cesarman, and Boshoff 2010). Distinct from traditional tumors, multifocal lesions of KS 
arise in the dermis in an independent manner (multicentricity) rather than through 
metastasis from primary tumor (Brooks 1986), and evidence supports that advanced KS 
lesions are polyclonal proliferations (Duprez et al. 2007). Consequently, KS evolves from 
red maculae (patches) through plaque-stage to nodules progressing locally or occur as 
widely diffused lesions in the patient (Gill et al. 1998; Ensoli et al. 2001). However, the 
clinical manifestation and morbidity of the disease is dependent on the particular 
epidemiological form of KS. 
 
 
2.1.2 Epidemiological variants of Kaposi’s sarcoma 
Histopathological appearance of all the four recognized KS forms are similar, but 
however, distinguishable according to epidemiological characteristics (Grayson and 
Pantanowitz 2008). The first identified form is the classical KS primarily affecting elderly 
men of Mediterranean area and Eastern European Jewish descent. Slowly progressing and 
rarely life-threatening, this indolent tumor occurs locally most often on the skin of lower 
limbs (Brooks 1986). A more detrimental form is the endemic KS found in subequatorial 
Africa, and common amongst men and children. Similar to classic KS, endemic KS 
manifests primarily as localized plaques and nodules on lower limbs, but visceral 
involvement is more common than in the classical form and in children it is associated 




More aggressive forms of KS manifest in the immunodeficient patients as 
disfiguring lesions widespread on the skin of the body and face. The high morbidity and 
mortality of these KS cases results from the occurrence of the lesions in visceral organs, 
such as lungs and gastrointestinal tract, leading to serious and fatal complications causing 
respiratory failure, hemorrhage, diarrhea or obstruction (Friedman-Kien 1981; Dezube 
1996). Iatrogenic KS among immunosuppressed transplant recipients was identified after 
recording the high incidence of KS in renal-transplant recipients and other patients 
receiving post-transplantation immunosuppressive therapy (Shepherd et al. 1997; 
Lebbe, Legendre, and Frances 2008). The fourth and the most notorious form 
recognized is the AIDS-associated KS, affecting immunosuppressed individuals with 
HIV infection advanced to AIDS.  
KS did not attract much scientific or public attention until the 1980s when in the 
western countries the outbreak of AIDS caused dramatic increase in KS cases. KS became 
the most common HIV-associated fatal neoplasm, causing an extensive health burden 
(Friedman-Kien 1981; Haverkos and Drotman 1985). Implementation of highly active 
antiretroviral therapy (HAART) in 1996 improved the prognosis of patients with AIDS-
associated KS considerably (Boshoff and Weiss 2002; Mocroft et al. 2004), and the 
incidence of AIDS-associated KS cases has rapidly declined in the western countries 
(Eltom et al. 2002; Ambinder and Cesarman 2007; Shiels et al. 2011). However, KS 
remains a significant health burden in sub-Saharan Africa due to persisting HIV epidemic 
and unavailability of antiretroviral therapy (Wabinga et al. 1993; Chokunonga et al. 
2000).  
As the malignancy was frequently manifesting in AIDS-patients, further studies 
on the role of HIV infection in KS pathogenesis were conducted. The association of KS 
and HIV infection was immense, and co-occurrence suggested HIV as a proximate cause. 
However, not all KS patients had HIV infection thus the notion of HIV as a main cause 
of KS was excluded (Beral et al. 1990). Classical and endemic forms of KS had no link 
to HIV infection, as no HIV proviral DNA was detected in the tumor biopsies. In addition, 
HIV-positive individuals had a varying risk of developing KS depending on the source of 
infection. KS occurrence was higher among homosexual or bisexual men with AIDS, 




sexual transmission (Martin et al. 1998). Consequently, researchers prospected a yet 
unidentified sexually transmitted human pathogen as a causative agent of KS (Beral et al. 
1990).  
 
2.2 Kaposi’s sarcoma herpesvirus 
2.2.1 Discovery of the causative agent of KS 
Chang and Moore, et al. discovered a novel herpesvirus from AIDS-KS biopsies the 
through representational difference analysis, isolating unique DNA sequences with no 
homologous sequence identified at the time in the current databases (Chang et al. 1994). 
The isolated DNA fragments of an unknown pathogen had similarities with the genomes 
of seven already known human herpesviruses (Longnecker and Neipel 2007). 
Consequently, the newly discovered virus was named human herpesvirus 8 (HHV-8), also 
known as Kaposi’s sarcoma herpesvirus (KSHV) due to evidence linking it in the 
pathogenesis of KS. In several subsequent seroepidemiological studies, strong 
concordance between KSHV infection and the incidence of KS has been confirmed 
(Kedes et al. 1996; Miller et al. 1996; Gao et al. 1996). KSHV DNA is invariably present 
in the biopsies from all the forms of KS, and likewise emergence of KS is not observed 
in the absence of KSHV infection (Chang et al. 1994; Boshoff, Whitby, et al. 1995; Dupin 
et al. 1995). These results indicate the necessary role of KSHV infection in the KS 
development.  
KSHV in the family of Herpesviridae is classified belonging to the subfamily of 
γ-2- herpesvirinae and is the first in the genus of Rhadinoviruses to infect humans (Russo 
et al. 1996; Moore et al. 1996). Close relation to a γ-1- herpesvirus Epstein-Barr virus 
(EBV) can be seen from the similar structure and genomic organization. EBV, also known 
as human herpesvirus 4 (HHV-4), is the aetiological agent of infectious mononucleosis, 
and the causal link between EBV and certain lymphomas have been revealed (Epstein, 
Achong, and Barr 1964; Henle, Henle, and Diehl 1968; Evans and Gutensohn 1984). 





2.2.2 KSHV seroprevalence mirrors the KS incidence 
KSHV seroprevalence in the general population is less than 10% in Northern Europe, 
Asia and United States. In the Mediterranean region, where classic KS occurs, it varies 
between 10-30% and in the sub-Saharan Africa region, where endemic KS is highly 
diffused, the rate is more than 50% (Mesri, Cesarman, and Boshoff 2010). Regardless of 
the region, homosexual men have consistently been shown to have the highest 
seroprevalence (Martin et al. 1998). In concordance with the seroprevalence rates, 
incidence of KS is relatively rare in low prevalence areas in the general population 
compared to some regions of African countries (Figure 2) or among homosexual men.   
Even though the seroprevalence rates are relatively common, the chance of 
developing KS for an individual in the general population is very low (Geddes et al. 1994; 
Hjalgrim et al. 1996; Iscovich et al. 2000). KSHV causes KS only in a minor fraction of 
infected hosts, indicating existence of additional co-factors. The KS risk is modulated by 
geographic, ethnic, genetic, immunologic and especially infectious cofactors. HIV 
infection increases the risk of developing KS considerably, as around 50% of KSHV and 
HIV double positive individuals will develop KS in 10-year period without HAART 
(Martin et al. 1998). Contribution of immunosuppression due to AIDS is immense, and 
represents the greatest co-factor in the KS pathogenesis (Boshoff and Weiss 2002). 
Among HIV-infected persons, the magnitude of immunosuppression, as evidenced by the 
declining CD4+ T-cell count, is predictive of development of KS (Dezube 1996; Krown, 
Testa, and Huang 1997; Renwick et al. 1998). Immunity impairment decreases the ability 
to maintain the cytokine homeostasis, and to respond to KSHV infection or KS tumor 
antigens (O'Connor and T-Scadden 2004). KSHV DNA increases in KSHV-positive 
patients as CD4+ count drops (McCune 2001; Tedeschi et al. 2001). Classical KS, having 
no link to HIV infection, has other cofactors involved in the disease progression. Genetic 
studies have reported increased risk in persons with higher interleukin-6 (IL-6) 
production or with differences in the human leukocyte antigen (HLA) complex 
participating in the regulation of immune system (Contu et al. 1984; Foster et al. 2000). 
Interestingly, a genetic predisposition to classical KS in Finland was reported in a 




binding domain of signal transducer and activator of transcription factor 4 (STAT4) 










2.2.3 Transmission of KSHV 
KSHV viral reservoirs are maintained in the cells of oral cavity, from where new viral 
particles are produced and significant amounts of virions are secreted in the saliva of 
infected individuals (Vieira et al. 1997; Pauk et al. 2000). There are several indications 
Figure 2. Geographical seroprevalence of KSHV and prevalence of KS. a. Seroprevalence rates 
in general population compiled from averages of multiple studies and b.  The standardized incidence 
of KS in males (obtained from the International Agency for Research on Cancer WHO publication: 
Cancer Incidence in Five Continents) Reproduced with the permission of the publisher from (Mesri, 




of KSHV shedding in saliva that suggest it as a natural source of transmission. In endemic 
KS areas, transmission from mother or other intimate care-taker to children before 
puberty provides evidence of non-sexual horizontal transmission, probably occurring 
through saliva (Mayama et al. 1998). In addition to childhood infections, KSHV is 
documented to be transmitted through blood transfusion and organ transplantation 
(Martin 2007). Nevertheless, especially sexual transmission between homosexuals with 
multiple sexual partners, is linked to higher risk of persistent infection and KS 
development than through heterosexual activities or parenteral transmission of the virus 
(Martin et al. 1998; Blackbourn et al. 1999). Even though KSHV infection is common 
among homosexual men, it is not increased among intravenous drug users, suggesting 
that transmission through blood inoculation is not a prominent route (Zhang et al. 1998). 
 
2.2.4 Life cycle of KSHV 
The hallmark of Herpesviridae is to establish lifelong infection in the host, displaying 
biphasic life cycle of quiescent latency and active lytic replication (Renne, Lagunoff, et 
al. 1996; Miller et al. 1997). In latency, the virus stays dormant within the host, expressing 
only a few genes and no viral particles are produced (Roizman and Pellet 2001). Turning 
off “unnecessary” viral proteins during latency serves as a strategy for the viruses to 
maintain persistent infection by avoiding host immune surveillance. Lifelong infection 
requires successful establishment and maintenance of latency as a viral episome in the 
nucleus of the host cell (Ballestas, Chatis, and Kaye 1999). However, reactivation from 
latency to lytic replication is necessary for the production of new viral particles to 
disseminate within the host and to spread by transmission to other individuals. The switch 
to lytic replication cycle initiates the expression of all the viral genes in a temporally 
organized cascade resulting in the release of progeny virions and inflammatory cytokines 
inducing host responses (Ensoli and Sturzl 1998; Renne, Lagunoff, et al. 1996). 
Characteristics of the herpesvirus family, including KSHV, is the very large size 
of the double-stranded DNA (dsDNA) genome and architecture of the virion structure 
consisting of icosahedral protein capsid, tegument proteins and lipid envelope (Chang et 




circulates to form a covalently closed episome including 140kb of coding information 
and 87 open reading frames (ORFs) (Russo et al. 1996; Renne, Lagunoff, et al. 1996). 
Some of the genes are apparently hijacked from the host cells, some are conserved among 
herpesviruses and some are unique for KSHV (Moore and Chang 2001). KSHV genes 
can be classified into four distinct kinetic stages, from latency to lytic viral transcription 
in an orderly cascade: (i)  latent genes are expressed during the quiescent latency; (ii) 
immediate early (IE) genes do not require prior viral protein synthesis for their 
expression; (iii) early (E) genes are expressed independent of viral DNA synthesis and 
(iv) late (L) genes whose expression is dependent on viral DNA synthesis (Roizman and 
Pellet 2001).  
 
2.2.4.1 Primary infection 
Primary KSHV infection is usually asymptomatic or symptoms are mild. However, in 
individuals with immunosuppression, the primary symptoms may be more notable (Luppi 
et al. 2002). In vitro, KSHV has been shown to have a broad cellular tropism infecting B-
cells, fibroblasts, macrophages, epithelial and primary endothelial cells (Akula et al. 
2001). When reaching the target cell, virus attaches to the cell surface molecule heparan 
sulfate (HS), which is a ubiquitous linear polysaccharide (Wang et al. 2001; Birkmann et 
al. 2001). The efficient entry into the host is achieved by fusion of the envelope with the 
host cell membrane (Sieczkarski and Whittaker 2002).  
After the entry into the host cell, the viral capsid is trafficked through the 
cytoplasm to deliver KSHV viral genome into the nucleus, where it is released from the 
capsid and immediately circularized to become an episome (Chandran and Hutt-Fletcher 
2007). In the nucleus of the infected cell, the virus initiates the lytic replication cycle and 
initiates transcription of lytic genes. Replication and transcription activator (RTA) has 
been identified through kinetic studies as an IE gene product, encoded by ORF50, the 
earliest viral gene to be expressed (Sun et al. 1999). Functional experiments have shown 
the necessary and sufficient role of RTA in initiation of KSHV lytic replication (Sun et 
al. 1998). However, it has been shown that during the de novo infection only a limited 




infection (Krishnan et al. 2004). This initial lytic activation, also indicated as the lytic 
burst, does not complete the lytic cascade to produce progeny virions but rather amplifies 
the viral episome and mediates immune modulation and anti-apoptotic functions. Indeed, 
concurrently with the lytic burst, expression of latent genes was shown to increase 
following the primary infection and were maintained during the course of infection, 
whereas expression of lytic genes subsequently decreased, indicating establishment of 
latency (Krishnan et al. 2004). 
 
2.2.4.2 Latency establishment 
During latency, KSHV genome persist as multiple copies of extrachromosomal episomes 
in the host cell nucleus. Viral gene expression is restricted to a few latent genes and 
miRNAs, which do not drive the production of progeny virions (Roizman and Pellet 
2001). Covalently closed circular episomes are hitchhiked to host chromatin by the 
latency-associated nuclear antigen (LANA), a multifunctional latent viral protein. To 
persist in the proliferating cells, episomes must replicate prior to cell division to maintain 
sufficient copy number within the new host cells. Once the host cell undergoes cell 
division, the latent episome relies on the host cell machinery and is replicated in 
synchrony with the cellular DNA (Ballestas, Chatis, and Kaye 1999). Also, efficient 
segregation of episomes to nuclei of the daughter cells after mitosis is necessary to avoid 
cytoplasmic degradation of the episomal DNA.  
 ORF73 has been identified as the gene encoding LANA (Kedes et al. 1997), and  
LANA plays a critical role in maintaining the viral episome (Ballestas, Chatis, and Kaye 
1999). LANA mediates the replication of KSHV DNA and the chromatin-binding 
domains of LANA tether the viral episome to mitotic chromosomes and help  to segregate 
the replicated episomes to progeny nuclei (Piolot et al. 2001; Ballestas and Kaye 2001; 
Grant et al. 2018) To achieve the crucial functions of episome persistence, LANA 
associates with different host cell proteins involved in DNA replication, transcriptional 
regulation and growth control (Friborg et al. 1999; Radkov, Kellam, and Boshoff 2000). 
However, latently infected cells tend to lose episomes upon culturing indicating that the 




Ganem 2004). Especially rapidly dividing cells and in vitro cultured explanted KS spindle 
cells lose viral genomes after only a few passages (Dictor et al. 1996). 
 
2.2.4.3 Reactivation from latency 
Latency can be disrupted upon appropriate induction or spontaneous reactivation of 
KSHV, displaying the nature of recurrent infectious cycle of herpesviruses. The 
reactivation of KSHV is triggered by the expression of the IE gene RTA, indicating its 
crucial role in the switch between latency and lytic replication (Zhu, Cusano, and Yuan 
1999). RTA is necessary and sufficient to activate the transcription of all the downstream 
IE, E and L viral genes (Sun et al. 1998). 
 In KSHV-infected cells, the interplay between RTA and LANA controls the 
switch from latency to lytic cycle. The earliest lytic gene RTA activates LANA to initiate 
establishment of latency. Reciprocally, LANA expression downregulates RTA by 
repressing its promoter (Lan et al. 2005). Epigenetic DNA methylation of the ORF50 
promoter facilitates the establishment and maintenance of latency in vivo (Chen et al. 
2001), thus keeping RTA at bay from further initiating lytic replication cascade. Also, 
viral non-coding polyadenylated nuclear (PAN) RNA is a regulatory transcript that 
mediates chromatin remodeling and targeting the repressed KSHV gene expression 
(Rossetto and Pari 2014; Aneja and Yuan 2017). Consequently, transcription of RTA is 
activated by epigenetic regulation, having a role in the reactivation of KSHV.   
Spontaneous reactivation of KSHV occurs periodically in the latently infected 
cells, and several mechanisms have been shown to trigger reactivation. In addition to 
above-mentioned immunosuppression due to organ transplantation or AIDS, also other 
viral co-infections and unbalanced inflammatory cytokines (Mercader et al. 2000; Vieira 
et al. 2001), hypoxia (Davis et al. 2001), oxidative stress (Ye et al. 2011), and certain 
chemicals have been shown to reactivate KSHV. Inducing chemical agents are used in 
the in vitro studies to achieve efficient reactivation. For example, sodium butyrate (NaB) 
is a histone deacetylase (HDAc) and releases the epigenetic repression of RTA by 





2.2.4.4 Productive lytic replication 
The lytic cycle is necessary for the virus to propagate and release infectious viral particles. 
The viral genome provides instructions for the production and assembly of progeny viral 
particles (Figure 3) and the host cell provides the machinery and precursor molecules to 
produce needed viral proteins and nucleic acids.  
RTA initiates the transcription of several downstream genes (Jenkins and 
Hoffman 2000). ORF45 is expressed as an IE gene in the beginning of the lytic cycle and 
its synthesis remains high through the late stages of the lytic replication (Zhu, Cusano, 
and Yuan 1999). Mostly cytoplasmic ORF45 protein is a highly phosphorylated 
component of the KSHV tegument, and significant amounts can be located in the 
encapsidated virions (Zhu et al. 2005). RTA also selectively activates promoter of E gene 
encoding a nuclear protein ORF57, also known as the mRNA transport and accumulation 
protein (MTA), which is multifunctional and conserved protein among herpesviruses, 
facilitating lytic replication (Bello et al. 1999; Lukac et al. 2001). ORF57 has been shown 
to have an essential role in lytic replication, as ORF57-null recombinant KSHV was 
unable to efficiently express several other lytic genes or produce virions (Han and 
Swaminathan 2006). ORF57 has been shown to facilitate translation and nuclear export 
of viral intronless mRNAs by recruiting cellular mRNA processing pathways, thereby 
enhancing lytic protein expression and virion production (Boyne, Jackson, and 
Whitehouse 2010; Schumann, Baquero-Perez, and Whitehouse 2016). One of the genes 
unique to KSHV (with no known sequence similarity to any other pathogen), K8.1, has 
been identified as a L gene through kinetic studies (Chandran et al. 1998). K8.1 encoding 
a structural envelope glycoprotein incorporated in the KSHV virion has an essential role 
in the production of new viral particles and it is acquired on the virion surface during 
budding from the plasma membrane (Birkmann et al. 2001). The L genes encode 
primarily viral structural proteins and reach the peak rates of protein synthesis after the 
onset of DNA replication (Jenkins and Hoffman 2000). Viral lytic replication amplifies 
the viral DNA through a rolling circle mechanism to replace the segregated episomes and 





All in all, during the productive lytic replication the newly synthesized viral 
dsDNA is incorporated into the preformed intranuclear capsid, which proceeds to 
cytoplasm to acquire the tegument structure. Final envelopment occurs by budding into 
Golgi-derived vesicles where the amplified progeny virions are assembled and released 
from the cells by fusing with the cell plasma membrane (Mettenleiter, Klupp, and 
Granzow 2009). The release of multiple encapsidated virus particles induces a cytopathic 
effect and is extremely lethal to the host cell. Released mature virions disseminate within 
the host to infect susceptible cells and can be transmitted to new hosts (Jenkins and 
Hoffman 2000).  
Figure 3. Map of the KSHV genome organization. The direction of the transcription is shown 
with the arrows, ORFs are indicated with numbers, genes unique for KSHV indicated with K. 
Genes highly expressed during latency are depicted with blue, and with purple those which are 
expressed in low levels with increase after switch to lytic replication. Lytic genes transcripted are 
depicted with grey and of those necessary for virion production are the capsid and envelope genes 
depicted with orange and green, respectively. Genes discussed in the text are highlighted with red. 





2.2.5 The contribution of KSHV latent and lytic phases to KS tumorigenesis 
The development of KS is initiated by the latent KSHV infection of the host cells, and it 
is considered that the latency program expressing only a few viral genes drives the 
tumorigenesis. In addition to the crucial role in the latent episome persistence (Ballestas, 
Chatis, and Kaye 1999), LANA contributes to KSHV-mediated oncogenesis by 
associating with a variety of host cell proteins of DNA replication, transcriptional 
regulation and growth control. Acting as a transcriptional co-factor, LANA has been 
shown to promote cell proliferation and survival by repressing or modulating tumor 
suppressor protein retinoblastoma (pRb) and p53 signaling pathways (Friborg et al. 1999; 
Radkov, Kellam, and Boshoff 2000; Sarek and Ojala 2007). The latency locus also 
encodes several other proteins; Kaposin, viral cyclin (v-cyclin), viral FLICE-inhibitory 
protein (vFLIP), and the viral-encoded microRNAs, which have been shown to contribute 
to KS tumorigenesis by promoting cell growth and inhibiting apoptosis (Muralidhar et al. 
1998; Verschuren et al. 2002; Sturzl et al. 1999; Sun, Zachariah, and Chaudhary 2003). 
Even though the latent KSHV gene expression supports the tumorigenesis of KS, it is not 
sufficient to sustain the development of the neoplasm.  
Most of the SC from KS lesions predominantly display latent KSHV infection, 
with only a minority of the cells undergoing spontaneous lytic reactivation (Figure 4) 
resulting in the expression of lytic viral proteins and virion production (Staskus et al. 
1997; Sun et al. 1999; Dupin et al. 1999). Low and declining antibody titers in individuals 
with functional immune surveillance also reflect the low rate of spontaneous reactivation 
(Martro et al. 2004). In vitro, infected SC tend to lose the viral episomes upon rounds of 
cell divisions. The role of lytic reactivation resulting in the release of infectious progeny 
is to counteract this inefficient episome maintenance by providing new viral particles that 
can infect new cells. The recruitment of newly infected cells in the tumors is necessary 
for sustaining the population of latent cells with viral genome, suggesting that lytic 
replication also contributes to KS tumorigenesis (Grundhoff and Ganem 2004). 
Furthermore, evidence for this notion is provided by the observed decrease in the 
incidence of AIDS-KS and regression of existing KS lesions in patients treated with the 




by binding specifically to the viral DNA polymerase expressed during the lytic phase, 
having no effect on latent cells. The ability of ganciclovir to inhibit KS progression 
indicates that KSHV lytic replication is necessary for KS to develop and sustain. 
Moreover, a study with nude mice showed that latent cells were not able to induce tumor 
formation, whereas ectopic expression of viral G protein-coupled receptor (vGPCR), 
expressed only during lytic replication, was able to give rise to tumors resembling human 













However, only a fraction of infected cells in KS lesions reactivate to produce 
KSHV-encoded lytic oncogenes and the survival of the lytic cells is only transient as the 
completion of the lytic cycle and release of infectious virions will kill the host cell. The 
common hypothesis is that lytically infected cells contribute to KS tumor development 
also by producing and activating signaling molecules which promote inflammation, 
modulate cell migration and stimulate angiogenesis in the KS lesions in a paracrine 
manner (Jochmann et al. 2012). Indeed, vGPCR enhances cell proliferation, angiogenesis 
and invasion, both in an autocrine and paracrine fashion (Bais et al. 1998; Arvanitakis et 
al. 1997; Jham and Montaner 2010). Similarly, a viral transmembrane protein K1 induces 
Figure 4. Expression of latent LANA and an early lytic protein ORF59 of KSHV 
in KS lesion biopsy. KS biopsy stained with specific antibody against LANA (left) and 
ORF59 (right). Majority of the cells are in latency, with only a few spontaneously 
reactivating to lytic replication, indicated with the early lytic protein ORF59. 





the secretion of cellular inflammatory cytokines, growth factors and matrix 
metalloproteinase-9 (MMP-9) in ECs (Wang, Wakisaka, et al. 2004). This so called 
paracrine effect, indicating secretion of cytokines and chemokines either encoded by the 
virus or induced by the expression of lytic genes, is a very important driver of KSHV 
pathogenesis (Jochmann et al. 2012).  
Generally, in immunocompetent individuals the sporadic spontaneous 
reactivation of KSHV is successfully cleared by a functional immune system (Simpson 
et al. 1996). The infection is under control, and majority of the infected cells avoid 
provoking host responses and elimination. As the virus is dependent on the host to survive 
and reproduce, it is not convenient for viruses to exhaust their residence. Disruption of 
the balance between viral infection and host immunity leads to agitated reactivation and 
increased lytic replication (Aneja and Yuan 2017). Consequently, more KS promoting 
lytic oncogenes are encoded and cytokines and chemokines secreted, in addition to 
enhanced production of new viral particles to infect nearby cells. In case of 
immunodeficient individuals, the CD4+ T-cell count and the host immune response is not 
sufficient to suppress the infection, and KSHV thrives uncontrollably (O'Connor and T-
Scadden 2004). Accordingly, AIDS patients are more susceptible to develop KS.  
In conclusion, KSHV latency drives oncogenesis of infected SC in KS lesions by 
inducing cell proliferation and reprogramming, and preventing apoptosis of infected cells, 
whereas KSHV lytic genes take part in the inflammatory and angiogenic phenotype of 
KS lesions. In addition to the crucial role in maintaining a population of infected cells, 
lytic replication triggers host signaling cascades leading to recruitment of inflammatory 
cells and secretion of cytokines and pro-angiogenic growth factors. Thus, both latent and 
lytic viral cycles contribute significantly to the tumorigenic microenvironment and 




2.3 KSHV-mediated endothelial cell reprogramming 
2.3.1 Angiogenesis and lymphangiogenesis  
The circulatory system consists of blood vessels and lymphatic vessels interconnected to 
form a complex and functional network able to deliver oxygen, nutrients and hormones 
throughout the body and to regulate fluid homeostasis and metabolic waste products.  In 
addition, the lymphatic vascular system is essential for absorption of dietary fat and 
immune cell trafficking as part of immune surveillance (Witte et al. 2001; Alitalo, 
Tammela, and Petrova 2005). The formation and growth of new blood and lymphatic 
vasculature, termed angiogenesis and lymphangiogenesis respectively, occurs mainly 
early during embryogenesis. Additionally, the plasticity of vasculature is retained in the 
adulthood, allowing tissue repair and remodeling, but also aberrant angiogenesis and 
lymphangiogenesis in pathological processes, such as in KS, may occur (Adams and 
Alitalo 2007).  
During angio- and lymphangiogenesis, vessels are formed by squamous ECs 
lining the interior surface of the new vessel as a continuous layer. Vascular smooth muscle 
cells and pericytes form the stabilizing outer layer. Endothelial precursor cells 
differentiate from mesodermal cells in embryogenesis and aggregate to form primary 
vascular plexus, which remodels through angiogenesis in a hierarchal vascular system. 
Maturation of blood endothelial cells (BECs) is executed to acquire tissue-specific 
specialization of vascular endothelium as a circulatory system (Gale and Yancopoulos 
1999; Alitalo, Tammela, and Petrova 2005). After the development of the cardiovascular 
system, subpopulation of ECs commit to lymphatic lineage and sprout from the 
embryonic cardinal veins to form the lymphatic system. (Wigle and Oliver 1999). 
Differentiated lymphatic endothelial cells (LECs) are distinct from BECs, by virtue of 
differential expression of specific transcripts. Blood and lymphatic vessel morphogenic 
events in both the normal development and in pathological remodeling are mediated by 
vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs). VEGFR-1 
and -2 expressions are specific for BECs whereas VEGFR-3 is predominantly expressed 




2.3.2 Transcription factor Prox1 
The prospero-related homeobox gene 1 (Prox1) is essential in acquisition of the LEC 
identity, contributing to the initial commitment during embryonic development. Prox1 
regulates LECs to differentiate from BECs in lymphangiogenesis (Yoo et al. 2012; 
Cancian, Hansen, and Boshoff 2013). Accordingly, Prox1 null mice embryos fail to 
differentiate the lymphatic vasculature, resulting in embryonic death (Wigle and Oliver 
1999; Wigle et al. 2002). In vitro, Prox1 has been shown to convert transcriptional 
program of cultured BECs towards the LEC phenotype, to adopt relevant function of 
lymphatic vasculature by upregulating LEC -specific gene expression, such as VEGFR-
3 (FLT4). In addition, several markers associated with the BEC phenotype have been 
shown to be suppressed by overexpression of Prox1, further promoting lymphatic 
endothelial phenotype development (Petrova et al. 2002; Hong et al. 2002). Eventually, 
in the differentiated BECs Prox1 is absent, whereas in LECs it is highly expressed, further 
supporting the notion that Prox1 is a master regulator of LEC differentiation and fate 
(Hong et al. 2004).  
Transcription factor Prox1 is localized on chromosome 1q32.2-q32.3 and it is 
composed of five exons and four introns, and codes for a protein with a predicted 
molecular mass of 82.3kDa (Elsir et al. 2012). The Homeo-prospero domain is highly 
conserved among vertebrates and Prox1 is the mammalian homolog of the Drosophila 
prospero gene, which specifies the cell fate in the insect neuronal system (Doe et al. 
1991). Likewise, Prox1 in humans has emerged as a key regulatory protein in the 
development of various organs, in addition to the lymphatic system. Binding of Prox1 to 
DNA allows transcriptional regulation of other genes required for the development of 
lens (Wigle et al. 1999), liver (Sosa-Pineda, Wigle, and Oliver 2000), pancreas (Burke 
and Oliver 2002), brain (Lavado and Oliver 2007), ear (Kirjavainen et al. 2008), and heart 
(Risebro et al. 2009). Furthermore, altered expression and function of Prox1 is associated 
with a number of human cancers. In different cancers, Prox1 showed both tumor 




2.3.3 Prox1 in KS 
KSHV infection of ECs activates a developmental genetic program specifying the LEC 
fate by altered Prox1 expression. Infection of differentiated BECs leads to lymphatic 
reprogramming by induction of LEC specific genes, including Prox1, and downregulation 
of blood vascular genes to acquire a partial LEC phenotype (Hong et al. 2004). 
Essentially, this leads to BEC forward reprogramming towards a more differentiated 
lymphatic phenotype, as Prox1 regulates BECs to differentiate into LECs in embryonic 
lymphangiogenesis. In a similar manner, KSHV-infected LECs shift towards blood 
vascular-like phenotype by downregulation of Prox1 (Wang, Trotter, et al. 2004). 
Infected LECs can be implied to undergo reverse reprogramming to a less differentiated 
blood vascular-like phenotype. The incomplete KSHV-mediated differentiation events 
of BECs and LECs according to expression of Prox1 are schematically summarized in 
Figure 5. 
 
Evidence supports the idea that Prox1 has an important role in mediating the 
effects of KSHV on bidirectional endothelial reprogramming resulting in the mixed 
identity (Yoo et al. 2012). Recent studies have provided insights to the molecular 
mechanisms of KSHV-induced changes of Prox1 expression in ECs. Several host 
signaling pathways and transcriptional factors have been identified to regulate Prox1, and 
multiple viral genes to deregulate the expression of Prox1 (Emuss et al. 2009; Yoo et al. 
Figure 5. KSHV-mediated host cell fate reprogramming towards KS spindle cell by altered 
transcriptional expression of Prox1. Differentiated BECs do not express Prox1, whereas 
differentiated mature LECs have high expression of Prox1. Upon infection, distinct endothelial lineages 
acquire mixed identity of KS spindle cells through endothelial reprogramming, as Prox1 expression is 




2010; Cheng et al. 2011; Yoo et al. 2012; Chang and Ganem 2013). Findings on KSHV-
mediated EC reprogramming elucidates the importance of Prox1 in KS tumorigenesis. 
The expression of Prox1 was found to increase from early stage KS to advanced nodular 
stage, where the majority (93.3%) of analysed neoplastic SCs were positive for Prox1, 
further suggesting the involvement of Prox1 in the pathogenesis of KS (Benevenuto de 
Andrade et al. 2014). 
 
2.3.4 Endothelial cell reprogramming towards KS spindle cell 
SC, the principal proliferating cell in advanced KS lesions, was first named as such in the 
1883 by German pathologist Köbner (Gessain and Duprez 2005). KSHV is latent in up 
to 90% of the spindle cells in the nodular advanced KS lesion and the productive virus 
replication is restricted to only a few spontaneously reactivating cells (Staskus et al. 
1997; Boshoff, Schulz, et al. 1995). KSHV infection of ECs causes rearrangement of the 
actin cytoskeleton producing elongated spindle-like morphology (Grossmann et al. 2006), 
changes in the glucose metabolism (Delgado et al. 2010), and proliferative advantage by 
altered growth rate and gene expression (Wang, Trotter, et al. 2004; Cheng, Pekkonen, 
and Ojala 2012).  KSHV-mediated acquisition of SC morphology is illustrated in Figure 
6. Furthermore, SCs display other tumorigenic properties such as increased angiogenic 
and migratory capacities (Wang and Damania 2008; Cheng et al. 2011; Ojala and Schulz 
2014). All of these characteristics of SC contribute to the diffusion of KS, highlighting 
the crucial role of KSHV-mediated reprogramming of ECs as a driver of the KS 
pathogenesis. 
BECs and LECs display morphological and functional similarities but are yet 
distinct from each other having significant plasticity and heterogeneity upon pathological 
reprogramming (Ferrara 1999; Adams and Alitalo 2007). KSHV infection modifies EC 
identity by manipulating the expression of endothelial-specific factors, among others 





The origin of SC has been under debate as the marker expression is highly 
heterogeneous. SC are believed to be of endothelial origin as they express several 
endothelial markers (Ensoli et al. 2001; Boshoff, Schulz, et al. 1995), however, they also 
display features of other cell lineages such as fibroblasts, macrophages and smooth 
muscle cells (Weich et al. 1991; Simonart et al. 2002). Whether spindle cells are originally 
derived from infected BECs or LECs is still under investigation although several studies 
argue for lymphatic endothelial lineage origin. In vitro studies have shown infected 
LECs to resemble the elongated morphology of KS spindle cells more distinctly than 
BECs do. Also, LECs support KSHV infection more efficiently harboring higher viral 
copy numbers compared to BECs, suggesting that LECs represents a preferred target 
of infection (Wang, Trotter, et al. 2004). Accordingly, KS occurs more frequently on 
the skin, in lymph nodes and mucosa abundant with LECs, but not in organs devoid of 
lymphatic vessels (Pantanowitz and Dezube 2008). Furthermore, gene expression 
signature of spindle cells resembles that of LECs with substantial expression of several 
LEC markers, including VEGFR-3 and podoplanin, when compared to the BEC 
specific markers (Weninger et al. 1999; Wang, Trotter, et al. 2004). 
However, the gene expression profiles of infected LECs and BECs show that 
KSHV induces transcriptional reprogramming of both cell types (Wang, Trotter, et al. 
2004; Hong et al. 2004). The transcriptional drift in both LECs and BECs results in 
Figure 6. Latent infection by KSHV causes endothelial cells to acquire spindle morphology. a, b. 
Human umbilical vein endothelial cells (HUVEC) prior (a) and after (b) infection with KSHV in 




mixed identity, somewhere in between the two phenotypes without reaching complete 
differentiation of one cell type towards the other (Yoo et al. 2012). Dysregulated 
transcriptional program explains the pleiotropy of marker expression in SC and the 
heterogeneity of KS lesions, contributing to Kaposi's sarcoma tumorigenesis (Gramolelli 




Figure 7. Schematic model of a KS lesion a-c. a. KSHV virions infect ECs. b. Early KS lesion with 
infected ECs reprogrammed towards SC phenotype producing cytokines attracting immune cells and 
inducing extravasation of red blood cells through angiogenesis. c. Late KS lesion with majority of SCs 
in latent phase and subset expressing oncogenic viral proteins and producing progeny virions allowing 
continuous reinfection of ECs attracted to the tumor. Reproduced with the permission of the publisher 





3 Aim of the study 
The switch from latency to productive lytic replication is an essential step in the 
pathogenesis of KS. Previous studies support the importance of lytic replication in the 
development and progression of KS (Martin et al. 1999; Grundhoff and Ganem 2004). 
Furthermore, lytic reactivation initiates the production of both viral and cellular 
inflammatory and angiogenic cytokines in the tumor microenvironment (Ensoli and 
Sturzl 1998). The expression of Prox1, the master regulator of lymphatic endothelial cell 
fate, is altered upon KSHV infection of ECs (Hong et al. 2004). Prox1 has an important 
role in the KSHV-mediated EC reprogramming towards the SC phenotype, which in turn 
supports the generation of a pro-angiogenic and inflammatory microenvironment, thus 
contributing to KS tumorigenesis (Yoo et al. 2012; Gramolelli and Ojala 2017). However, 
the role of Prox1 in lytic reactivation has not been assessed. Preliminary studies in our 
group carried out in KSHV-infected ECs indicate that Prox1 depletion leads to a decrease 
in lytic reactivation, thus suggesting a positive role for Prox1 in KSHV reactivation. 
The aim of the thesis was to elucidate the role of Prox1 in KSHV reactivation from 
latency and the effect of Prox1 in lytic replication. My aim was to investigate the effect 
of ectopic expression of Prox1 on viral reactivation and lytic replication efficacy, and to 
measure the effect on production of progeny viral particles. The effort of gaining deeper 
understanding of the role of Prox1 in KSHV life cycle can potentially open new 








4  Materials and methods 
4.1 Cell lines 
iSLK.219 rKSHV is a RTA -inducible SLK cell line, stably infected with a recombinant 
KSHV.219. SLK cells are originally derived from an oral KS lesion biopsy of a HIV-
negative renal transplant KS patient (Herndier et al. 1994; Siegal et al. 1990). These cells 
were reported to be uninfected cells of endothelial origin and when implanted in mice 
they formed highly vascularized tumors reminiscent of KS (Dr. J. A. Levy United States 
(Herndier et al. 1994) However, more recently when the authenticity of SLK cells was 
tested, it was shown that these cells have been cross‐contaminated relatively early in their 
passage and are of epithelial‐cell origin, indistinguishable from the clear‐cell renal‐cell 
carcinoma cell line Caki‐1. Therefore, the SLK cell line is not a suitable model for 
endothelial tumor cell biology. However, these cells are fully permissive for the KSHV 
latent and lytic replicative cycles and retain their utility for the study of KSHV gene 
expression (Sturzl et al. 2013).  
SLK were engineered to express RTA under a TET (tetracycline) responsive 
promoter, meaning that RTA promoter is activated after induction with doxycycline 
(iSLK) (Myoung and Ganem 2011). Cells were latently infected with recombinant 
KSHV.219 virus (iSLK.219) expressing green fluorescent protein (GFP) by the 
constitutively active human elongation factor 1- (EF-1) promoter and red fluorescent 
protein (RFP) under the control of RTA-responsive polyadenylated nuclear (PAN) 
promoter, expressed only during lytic replication  (Vieira and O'Hearn 2004). In addition, 
pac-gene under control of the Rous sarcoma virus (RSV) promoter is inserted to give 
puromycin-resistance as an selection marker (Myoung and Ganem 2011). This cell line 
is a useful and well-characterized model to study KSHV latency and viral replication due 
to the tight latent program and to the efficient and synchronous induction of lytic 
reactivation by the Doxycycline-dependent induction of the RTA gene. Furthermore, 
latent and lytic expression can be monitored by the expression of GFP and RFP, 
respectively. A schematic diagram of the recombinant cell line iSLK.219 is presented in 













Human osteosarcoma cell line U2OS was used as a naïve, uninfected cell line to 
study KSHV infection kinetics and efficacy of infection in the virus release assays. This 
cell line is highly susceptible to KSHV infection. Human embryonic kidney cell line HEK 
293FT (National Cancer Institute, LCO technical files) is a fast-growing variant of the 
parent cell line (HEK293T) and was used for generating high-titer lentivirus. TREx-RTA 
BCBL-1, a KSHV-positive B cell line from a PEL patient (Renne, Zhong, et al. 1996) 
with a Dox-inducible RTA construct, was used to produce wtKSHV for the infection 
kinetics assay. 
Figure 8. Schematic diagram of the recombinant cell line iSLK rKSHV.219 a, b.  
a. Schematic diagram of KSHV.219 genome with magnified structure of the inserted construct 
between ORF57 and K9 at non-coding area. The inserted cassette includes the RFP gene under 
PAN promoter, GFP gene under EF1-α promoter, and puromycin resistance gene under RSV 
promoter. The numbers indicate kilobases and direction of the transcription is shown by the 
arrows. Reproduced with the permission of the publisher from (Vieira and O'Hearn 2004).  
b. Phase and fluorescent microscope (10x) images of iSLK.219 cells upon latent infection 





BCBL1 cells were grown in RPMI 1640 medium and iSLK.219 rKSHV, U2OS and 
HEK 293FT cells were grown in Dulbecco modified Eagle´s medium (DMEM), both 
purchased from Lonza and supplemented with 10% Foetal Calf serum (FCS) and 1% L-
Glutamine. iSLK.219 cells were cultured with puromycin 1µg/mL (Sigma P8833) for 
selection of infected cells. In addition, G418 solution (Roche) in dilution 1:100 and 
hygromycin (Thermo Fisher Scientific) in dilution 1:100 was added to the iSLK.219 cells 
to allow the activation of RTA promoter. All cells were propagated at standard conditions 




Primary antibodies used in Western blotting, immunofluorescence staining or in 
immunoprecipitation of this study are listed in Table 1.  
Table 1. Primary antibodies. 
Antibody 
against/ stain 
description source/reference Working 
dilution 
Used in 
β -actin Mouse 
antibody 
Santa Cruz (sc-47778) 1:500 WB 
GFP Rabbit 
antibody 
A gift from Ari Helenius 1:2500 IF 
K8.1 Mouse 
antibody 



















Cell Signaling (9B11) 1:20 IP 
ORF45 Mouse 
antibody 


























In this study, Self-Inactivating (SIN) vector was used to transfer the genetic material to 
the target cells. Packaging plasmids pLp1, pLp2 and pLp/VSV-G were used together with 
pSIN plasmid carrying the gene of interest (Prox1 WT or MUT). Heterologous coat G 
glycoprotein from vesicular stomatitis virus (VSV-G) was used in place of the native 
HIV-1 envelope, and viral enhancer and promoter sequences have been deleted from SIN 
vectors. These modifications increase the safety of the lentiviral vector system.  
N-terminal MYC-tagged Prox1 wild-type (WT) and DNA-binding deficient Prox1 
mutant (MUT) were cloned into the pSIN lentiviral vector. Mutations N626A and N628A 
in Prox1 MUT were introduced by site-directed mutagenesis as described in (Petrova et 
al. 2002). Confirmation of mutations by sequencing (GATC Biotech, MyGATC) of the 
insert was performed to both Prox1 WT and MUT. 
 
4.4 Virus production, infections, transduction and transfection 
Wild-type wtKSHV was produced from TREx-RTA BCBL-1 cells stimulated with 
1µg/mL doxycycline. After three days, the supernatant was filtered and the virus collected 
by centrifugation (SW32, 22,000 rpm at 4℃ for 2 h), and resuspended in PBS. Cells were 
infected with wtKSHV 20µg/mL in the presence of polybrene (Sigma H9268) 8µg/mL 
and spinoculated 450g for 30min at RT (Eppendorf Centrifuge 5804R). Polybrene acts 
by neutralizing the charge repulsion between cell surface sialic acid and virions, 
increasing infection efficiency (Davis et al. 2004). 
Recombinant KSHV.219 was produced as described in (Vieira and O'Hearn 
2004). Briefly, lytic reactivation was induced with 0.05µg/mL of doxycycline (Dox) 
(Sigma D9891) (Myoung and Ganem 2011).  In addition, sodium butyrate (NaB) 3.3mM 
was used to enhance the reactivation (Vieira and O'Hearn 2004).  
For production of lentiviral particles, HEK 293FT cells were transfected using 
Lipofectamine 2000 (Life Technologies) according to manufacturer’s instructions with 




WT or MUT. Three days post-transfection virus was collected with PEG-it Virus 
precipitation (System Biosciences) according to manufacturer’s instructions. iSLK.219 
cells were transduced with lentiviruses in the presence of polybrene 8µg/mL. pSIN, Prox1 
WT or MUT lentiviruses were used at a 1:500 dilution. Next, cells were spinoculated 




Real time quantitative Polymerase chain reaction (RT-qPCR) was used to measure gene 
expression levels from extracted total RNA of the samples. Cells were collected from 
culture and extraction of RNA was performed using NucleoSpin RNA II kit (Macherey 
Nagel). The RNA concentration was measured with NanoDrop (Thermofisher). Using 
thermal MyCycler (Bio-Rad), total RNA was reverse-transcribed to cDNA with final 
reaction volume of 50 µl. cDNA synthesis was achieved using 1 µg of total RNA, 2.5µl 
dNTP (AB 1831597), 11.0µl MgCl2 (Thermo Scientific 00292623), 5.0µl 10X RT buffer 
(AB 1402114), 1.0µl RNAse inhibitor (AB 566718), 10.0µl Oligo (Invitrogen 1832147), 
and 1.25µl MultiScribe RT (Applied Biosystems 00472355) diluted in nuclease free H2O 
up to volume of 19.3µl. 
Transcription levels were measured in three technical replicates using Taqman 
Gene Expression Assays (Applied Biosystems) with unlabelled primers (listed in Table 
2) and SYBR Green (2x) reaction mix (Fermentas) in the StepOnePlus Real Time PCR 
system (Applied Biosystems). The amplification was performed in LightCycler480 PCR 
384 multiwell plate (Roche) with total volume of 10 µl per well, of which 2 µl cDNA and 
8 µl mastermix. The PCR thermocycling included an initial denaturation at 95 °C for 10 
minutes followed by 50 annealing cycles, each consisting of 15 seconds at 95 °C, 30 
seconds at 60 °C and 30 seconds at 72 °C, and a final extension step at 72 °C for 7 minutes. 






Table 2. Primers used in this study. 
Target Forward Reverse 
Actin  TCACCCACACTGTGCCATCTACGA CAGCGGAACCGCTCATTGCCAATGG 
K8.1 AAAGCGTCCAGGCCACCACAGA GGCAGAAAATGGCACACGGTTAC 
ORF45 CCTCGTCGTCTGAAGGTGA GGGATGGGTTAGTCAGGATG 
ORF57/MTA TGGACATTATGAAGGGCATCCTA CGGGTTCGGACAATTGCT 
Prox1 TGTTCACCAGCACACCCGCC TCCTTCCTGCATTGCACTTCCCG 
 
4.6 Immunoblotting 
The expression of selected proteins present in the cellular lysates were detected with 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) followed by 
Western blotting (WB). 
Cells were lysed with RIPA buffer (150mM-NaCl; 1%-Igepal CA630-0.5% Na-
deoxycholate-0.1% SDS-50mM; Tris-HCl-PH 7.8) supplemented with proteinase and 
phosphatase inhibitors (Pierce™ 88666, 88667), and cleared by centrifugation. The 
concentration of protein from each cleared sample was measured with Protein assay dye 
reagent concentrate (Bio-Rad) and BioPhotometer (Eppendorf), and accordingly used to 
obtain equal amount of protein in all the samples included in the experiment. Loading 
buffer 5XLaemmli was mixed with 2-mercaptoethanol and added to the cell extracts, 
which were boiled 5 min in 99℃. After cooling down at RT, samples and PageRuler Plus 
Prestained protein ladder (Thermo Scientific) were loaded on Criterion TGX precast 
polyacrylamide gel (Bio-Rad), and run at 55mA for approximately 40 min. After the 
electrophoresis run, proteins in the gel were transferred to nitrocellulose membrane (Bio-
Rad) using trans-blot Turbo Transfer system (Bio-Rad).  
Membranes were blocked in 5% non-fat dry milk in Tris-buffered saline with 
0,1% Tween (TBS-T) solution for 1h in rocking table. Primary antibody incubations were 
performed in the blocking solution overnight (O/N) at 4℃. After, the membranes were 
washed and appropriate HRP-conjugated lgG secondary antibodies (Cell Signalling, 
Millipore) were incubated for 1h in blocking solution at RT. The membranes were washed 




in this study are listed in Table 1. The luminescent signal from immunoblotted proteins 
was detected using WesternBright Sirius detection kit (Advansta) and ChemiDoc MP 
imaging system (Bio-Rad). The relative expression of proteins was determined from 
generated images, and β-actin (42 kDa) was used as a loading control.  
 
4.7 Immunofluorescence staining 
Immunofluorescence (IF) staining was performed in 96-well black bottom plate (Perkin 
Elmer). After fixing cells with 4% PFA for 20min in RT, cells were washed 3x with 0,5% 
bovine serum albumin (BSA) in PBS to block unspecific staining. Permeabilization was 
done with 0,2% Triton-X 100 (Sigma SLBD7186V) simultaneously with nuclei 
counterstaining using 1ug/mL of Hoechst 33342 (Fluka Biochemika 14533) in PBS for 
10 min dark incubation at RT. Between all incubations, the cells were washed 3x with 
0,5% BSA in PBS. Primary antibodies for specific staining of proteins were incubated in 
the dark for 1h at RT. Appropriate secondary antibodies conjugated to Alexa Fluor 488, 
594, 647 stains obtained from Life Technologies (Thermofisher) were incubated with 
0,5% BSA in PBS in dilution of 1:1000 for 1h at RT. Finally, the cells were washed 2x 
with 0,5% BSA in PBS and once with only PBS before imaging. Thermo Scientific Cell 
Insight Hight Content Screening system provided by Biomedicum Imaging Unit (BIU) 
was used to image immunofluorescence signal from the plates. Antibodies used in the 
study are presented in Table 1.  
 
4.8 Co-immunoprecipitation 
For immunoprecipitations, cells were lysed in the IP lysis buffer (150mM-NaCl; 50mM-
Tris-HCl-pH 7.8; 0.2%-NP40 Igepal; 1% glycerol; 0.5mM-EDTA) supplemented with 
complete proteinase and phosphatase inhibitory cocktails, and the whole cell extracts 
were cleared by centrifugation for 20min at 4℃. Next, aliquots were taken for inputs and 
the rest of the extracts were incubated either with a MYC antibody (to immunoprecipitate 
Prox1), or a control mouse lgG antibody O/N in 4℃ rotating. Protein G beads (Abcam) 




wash with IP buffer. Immunoprecipitated and total proteins were subjected to SDS-PAGE 
and transferred to nitrocellulose membranes for WB. Antibodies used in the study are 
listed in the Table 1. 
 
4.9 Statistical analysis 
For statistical evaluation of qRT-PCR data, the logarithmic values were converted to 
linear log2 scale values by using double delta CT (2-ΔΔ CT) method, designed to analyse 
the relative changes in gene expression. Threshold cycle (CT) is defined as the PCR cycle 
at which the fluorescent signal of the reporter dye crosses an arbitrarily placed threshold 
(Livak and Schmittgen 2001). Reference gene β-actin, used as internal control, was 
accounted in the calculations to correct differences in quality, in cDNA and PCR 
synthesis efficacy between samples. Graphical representations and statistical analysis 
were generated with GraphPad Prism Software v6.0c with RT q-PCR data presented as 
the means ± standard deviation (SD). Differences between means were analysed with 
One-way ANOVA test corrected for multiple comparisons, Prox1 pSIN WT, MUT and 
mock were compared to pSIN VC. A difference between two means was considered 
significant when *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.  
For statistical evaluation of virus release assay, the virus loads were measured as 
percentage of GFP -positive (virus-infected) cells relative to the number of nuclei. 
Quantification was carried out with CellProfiler Software v2.1.1 and output of 2 
biological replicates was processed by calculating average of infected cells of every 
dilution from 3 technical replicates all having 9 images. Dilution having infected cells 
between 10-20% of the population was selected for statistical analysis as with this 
percentage of GFP-positive (virus-infected) cells it is possible to better appreciate and 
quantify the differences among the different samples. Graphical representations and 
statistical analysis were generated with GraphPad Prism Software v6.0c and data 
presented as the means ± standard deviation (SD). Differences between means were 
indicated as p-values tested with One-way ANOVA for multiple comparisons, all 
conditions were compared to pSIN and mock. A difference between two means was 





5.1 Prox1 increases lytic gene expression 
To elucidate the role of Prox1 during KSHV reactivation, the levels of lytic transcripts 
both during latency and during lytic reactivation in cells ectopically expressing of Prox1, 
was measured. The study was conducted in iSLK.219 cells, which do not endogenously 
express Prox1 and are stably infected with the recombinant virus. To this end, iSLK.219 
cells were seeded on a 24-well plate and the next day transduced as described with 
lentivirus coding for Prox1 WT or MUT, unable to bind DNA. In addition, pSIN VC and 
polybrene-treated cells (mock) were used as a negative control. A day after, cells were 
left untreated (latent) or reactivated with Dox. Cells induced were incubated for 48h, and 
RNA extraction and gene expression measurement by RT-qPCR were performed. Prox1 
expression is relatively high in Prox1 WT and MUT, but not in the mock, indicating 
successful transduction (Figure 9). Prox1 MUT expression is higher than Prox1 WT even 
though the transduction was performed in the same way and with the same pSIN vector 
concentration. 
Data obtained from RT-qPCR indicate that an increase in lytic gene expression is 
already detectable during latency in the presence of Prox1 WT (Figure 9a). This is 
surprising since no RFP, which the recombinant virus expresses upon reactivation, was 
detected in Prox1 WT expressing iSLK.219 prior to Dox treatment. In contrast, Prox1 
MUT-expressing cells had very low levels of lytic mRNAs in the absence of Dox, 
probably due to the dominant negative effect. After the induction of lytic reactivation by 
Dox, enrichment in the relative mRNA levels of lytic markers was observed, differing 
significantly between Prox1 WT and the controls, (Figure 9b). Relative expression levels 
of viral immediate-early ORF45 and early ORF57 are higher in the presence of Prox1 
WT compared to other conditions. Especially the mRNA level of late expressed K8.1 is 
significantly increased with Prox1 WT, up to 13-fold compared to mock (Figure 9b). The 
observation that similar mRNA levels of lytic markers and Prox1 between pSIN VC and 
the mock ensures that pSIN does not have significant effect on relative expression of lytic 




that the relative latent and lytic relative expression levels are not comparable (Figure 9a 
and b). Thus, latent controls (pSIN and mock) express very low levels of lytic markers, 
allowing the detection of even a slight increase in the lytic gene expression of Prox1 WT.  
On the other hand, the lytic controls, VC and mock, themselves yield moderate levels of 
lytic gene expression after reactivation, meaning that lytic gene expression levels of Prox1 
WT are indeed very high.  
In conclusion, the gene expression analysis suggests Prox1 as a positive regulator 
of KSHV lytic gene expression. The increased lytic gene expression in both latent and 
reactivated cells indicate Prox1 having a role in both phases of the KSHV life cycle. 
However, the effect of Prox1 on viral lytic expression prior to and after the reactivation 











Figure 9. Prox1 ectopic expression increases lytic gene expression a, b. iSLK.219 seeded at a 
density of 1.25x105 cells per well in a 24-well plate and transduced with pSIN Prox1 WT, MUT or 
pSIN VC or treated with polybrene only (mock), a. untreated (latent) and b. reactivated with Dox 
24h (lytic), mRNA levels of indicated transcripts normalized to β-actin are shown. Bars indicate 





5.2 Prox1 increases lytic protein expression 
To further study the effect of Prox1on viral lytic protein expression, immunoblotting was 
performed to study expression of selected lytic markers at protein level in latent and 
reactivated iSLK.219 cells. Cells were seeded and transduced the next day either with 
Prox1 WT or MUT as described above. Reactivation was performed the following day 
either with only Dox or using Dox in combination with NaB to achieve maximal level of 
reactivation. Polybrene-treated cells (mock) was used as a negative control. Cells induced 
with Dox+NaB were incubated for 24h, and cells induced only with Dox for 48h. The 
cells were harvested in RIPA buffer and processed for SDS-PAGE and Western blotting. 
Viral protein expressions of selected latent and lytic markers in addition to Prox1, to 
assess the efficiency of transduction, and β-actin as a loading control were analysed. 
The results from RT-qPCR (Figure 9) showed differences in the expression of 
lytic markers prior to reactivation, however, this was not observed in the immunoblot 
(Figure 10). The difference is likely due to RT-qPCR being more sensitive in detecting 
low levels of gene expression compared to immunoblotting. After reactivation, the 
specific bands for the selected lytic proteins ORF45 (60-80kDa), ORF57 (55kDa) and 
K8.1 (40kDa) are visible. Expression of both, ORF45 and ORF57, did not indicate a clear 
difference between Prox1 WT and MUT. However, the expression of the structural 
envelope protein K8.1 was substantially more abundant upon Prox1 WT expression. 
Interestingly, even though Prox1 WT expressing cells have the highest lytic protein 
expression, it was also relatively high with Prox1 MUT but not in the mock. This indicates 
that even though Prox1 MUT is devoid of DNA binding activity, it can promote lytic 
protein expression. However, the lytic promoting effect can be detected only at a protein 
level, as increase in lytic markers was not observed at transcript levels (Figure 9b).  
Latency-associated nuclear antigen LANA is encoded by ORF73 throughout the 
KSHV life cycle, in both latent and lytic phases. This was confirmed in the LANA blot 
showing a series of bands between 230 and 200 kDa (Figure 10a). As the name implies, 
the main function of LANA is the viral episome maintenance, and it is localized in the 
nucleus of latently infected cells (Ballestas, Chatis, and Kaye 1999). However, the third 




described cytosolic LANA (Toptan et al. 2013; Zhang et al. 2016). Observed only during 
lytic cycle, these N-terminally truncated isoforms of LANA are present in the perinuclear 
and cytoplasmic sites of KSHV-infected cells. Again, Prox1 MUT expression is higher 
than Prox1 WT as it is more stable than WT, due to slower degradation and resulting in 
higher protein levels (Dr. Silvia Gramolelli, personal communication). Expression of 
Prox1 (80-100kDa) is strongly downregulated after the reactivation (Figure 10a). 
iSLK.219 can be induced to reactivation with Dox only (Figure 10a), however, 
more efficient induction of reactivation by addition of NaB shows a strong enrichment of 
lytic proteins, also in the mock (Figure 10b). Enhancement of reactivation with NaB 
causes such a strong viral protein expression that differences in the levels of ORF45 and 
ORF57 are not anymore detectable. Nevertheless, the protein expression of K8.1, 
translated later in the lytic replication cycle, is distinctly higher with Prox1 WT compared 
to Prox1 MUT and mock. Taken together, these results are consistent with the lytic 
mRNA expression analysis and implicate that Prox1 has a promoting effect on KSHV 










Figure 10. Prox1 ectopic expression increases lytic protein expression a, b.  
iSLK.219 seeded at a density of 5x105 cells per well in a 6-well plate (Greiner bio-one) and 
transduced with Prox1 pSIN WT or MUT or left untransduced (mock), left blots: untreated (latent; 
indicated with -) and right: reactivated with Dox for 48h (a) or Dox/Nab 24h (b), protein expression 





5.3 Prox1 enhances lytic reactivation 
The effect of Prox1 on lytic reactivation was studied in more detail using iSLK cells 
infected with the recombinant virus rKSHV.219 which in latency expresses GFP and 
upon reactivation also expresses RFP (Vieira and O'Hearn 2004). iSLK.219 rKSHV cells 
were seeded on black bottom 96-well plate and the next day, cells were transduced with 
pSIN lentivirus either empty or expressing Prox1 WT or a mutant, which does not bind 
to DNA. The virus was reactivated by inducing RTA expression upon Dox treatment for 
24h. Reactivation levels (RFP) of iSLK.219 cells, ectopically expressing either Prox1 WT 
or MUT, were compared to pSIN VC. In addition, selected lytic markers and latency-
associated LANA were detected with immunofluorescence staining to observe the 
reactivation at single cell level. 
By observing differences in the number of RFP positive cells by high-throughput 
images, shown in Figure 11, cells expressing Prox1 WT display the highest reactivation 
levels. Immunofluorescence signal of viral nuclear protein ORF57 can be observed in 
slightly higher abundancy upon Prox1 WT ectopic expression (Figure 11). More striking 
differentially expressed lytic protein in Prox1 WT-expressing iSLK.219 cells is K8.1,  
structural envelope glycoprotein incorporated to virions (Birkmann et al. 2001). Viral 
latent gene product LANA is present in the nuclei of infected cells and expressed in all 
conditions (Ballestas, Chatis, and Kaye 1999). The efficacy of Prox1 introduction by 
transduction can be observed from staining with Prox1-specific antibody. As seen from 
Figure 11, Prox1 is present only in WT and MUT, but not in pSIN VC or mock and Prox1 
MUT expression is higher than Prox1 WT. 
This lytic reactivation assay further indicates Prox1 as a positive regulator of KSHV 
reactivation from latency. Reactivation through activation of RTA initiates the lytic 
replication cycle and the expression of lytic markers downstream of RTA is stronger in 







Figure 11. Prox1 ectopic expression increases rate of lytic reactivation and expression of lytic 
markers. iSLK.219 seeded on black bottom 96-well plate (Perkin Elmer) at density of 5x103 cells 
per well were transduced with pSIN prox1 WT, MUT or pSIN, and reactivated with Dox for 24h 
were fixed and stained with the indicated antibodies (green) nuclei were counterstained with 





5.4 Prox1 enhances KSHV release of infectious virions 
Previous results have revealed that Prox1 is a positive regulator of lytic reactivation 
enhancing both the lytic gene and protein expression. The successful completion of the 
lytic cascade leads to the assembly and release of newly synthesized viral particles able 
to infect new target cells. Therefore, we next asked whether ectopic expression of Prox1 
WT or MUT would lead to higher viral yields, quantitatively measured in terms of 
efficacy in infecting naïve cells.  
A day before seeded iSLK.219 cells were either left untransduced (mock) or 
transduced with pSIN Prox1 WT or MUT or pSIN VC and 24h later reactivated as 
indicated. Reactivation was verified by measuring the RFP signal under a fluorescent 
microscope (data not shown). Cells induced with the combination of Dox and NaB were 
incubated for 48h, and cells induced only with Dox for 72h. The virus-containing 
supernatant was then collected and used to infect naïve U2OS cells seeded the day before 
on a 96-well plate. Infection by supernatant was done as serial dilution in the presence of 
polybrene to enhance the infectivity. Schematic representation of the virus release assay 
workflow is depicted in Figure 12. After incubating 24h, GFP intensity was analysed in 
the target U2OS cells. The signal of GFP was enhanced with immunofluorescence 
staining and nuclei were visualized with Hoechst 33342 (Figure 13a, c). Virus loads were 









Quantification of the GFP-positive cells from the whole cell population calculated 
as a percentage of infected cells revealed that Prox1 WT significantly increased the virus 
release, more than 10-fold (Figure 13b, d). Addition of NaB enhances the reactivation 
causing increase of newly infected cells from 14% to 90% of cells when compared to 
cells infected with a sup from reactivation done only with Dox. Due to a very high 
infection rate, it is more reliable to quantify the virus release from cells infected with the 
more diluted supernatant (Figure 13c area indicated in red). Furthermore, enhancement 
with NaB causes quite a strong increase in the virus release of reactivated cells with Prox1 
MUT (Figure 13d), not observed in cells reactivated using only Dox (Figure 13b), that 
represents a more reliable way to observe and interpret the virus release results. 
Figure 12. Schematic representation of virus release assay workflow. Latent iSLK rKSHV 
seeded at a density of 5x105 cells per well in a 6-well plate (Greiner bio-one) were transduced with 
Prox1 pSIN WT or MUT, and mock, depicted with GFP (green) and treated with Dox or Dox+NaB 
for reactivation depicted as RFP (red). Viral particles were shed to the culture media, and the 
supernatant was used to latently infect U2OS, seeded day before at a density of 8x103 cells per well 
in a 96-well plate (Perkin Elmer), in serial dilution. Virus loads are measured as GFP% (infected)-




In conclusion, Prox1 WT, but not MUT, significantly increased the release of 
infectious virions and consequently the infection rate of naïve cells. Hereby the virus 
release assay indicates that infected cells expressing Prox1 produce more viral progeny, 
resulting in more efficient dissemination and infection of new host cells.  
 
 
Figure 13. Prox1 ectopic expression enhances KSHV release a-d. KSHV loads of U2OS infected 
with serial dilutions of supernatant from iSLK rKSHV transduced as indicated and treated with a, b 
Dox 72h or c, d Dox+NaB 48h is shown. a, c. High-throughput images of infected U2OS cells, with 
each square representing one well. Red areas highlight the dilution used in analysis. b, d. Bars indicate 
average virus loads measured as GFP% (infected)-positive cells shown as mean ± SD 9 




5.5 Time course of Prox1 expression during KSHV primary infection 
To investigate the expression levels of Prox1 during the KSHV infection cycle, infection 
kinetics assay was performed. U2OS cells infected with wtKSHV and followed during 
the indicated time-scale from the onset of KSHV infection to latent infection 
establishment. Prior to infection, lysate of uninfected cells (timepoint 0h) was harvested 
in RIPA buffer. Infected cells were harvested at 8 ,12, and 24h and after 2, 3, 4 and 6 days 
(d). The expression of Prox1, KSHV IE gene RTA and LANA were measured by 
immunoblotting with β-actin as a loading control. The results are shown in Figure 14. 
U2OS cells endogenously express Prox1 at very low, nearly undetectable levels 
prior to infection (Dr. Gramolelli, personal communication, Human protein atlas). Viral 
proteins are not expressed at 0h as the sample was obtained before addition of infectious 
particles. After the infection with wtKSHV, expression of Prox1 increases rapidly within 
a day reaching a peak concurrently with RTA (110-130 kDa) at 24h post infection (p.i.) 
(Figure 14). The expression of LANA progressively but moderately increases and likely 
represses the RTA promoter to establish latency and to maintain episomes in the newly 
infected cells, as described before (Chen et al. 2001; Lan et al. 2005). Most importantly, 
after the lytic burst, Prox1 expression progressively decreases. Similarly, the 
downregulation of Prox1 48h after reactivation was observed in a previous assay (Figure 
10a). Within a week, as the acute infection has passed and latency is established by 























5.6 Co-immunoprecipitation of Prox1 and RTA 
Since our data indicated that Prox1 enhances the RTA-dependent reactivation and 
transcription of KSHV lytic genes, we asked whether Prox1 achieves this by interacting 
with RTA. To this end, co-immunoprecipitation of Prox1 and RTA was performed. 
iSLK.219 cells, seeded on a 6-well plate, were transduced with pSIN lentivirus expressing 
Prox1 WT or MUT and reactivated by inducing RTA expression with Dox treatment for 
24h, as described above. The cells were harvested in IP buffer and processed for co-
immunoprecipitation and immunoblotting. 
 The obtained data indicates that RTA was immunoprecipitated with Prox1 WT, 
but only weakly with Prox1 MUT, devoid of the DNA binding activity (Figure 15), 
suggesting that Prox1 and RTA interact with each other. However, these results are 
Figure 14. Prox1 expression kinetics during KSHV primary infection. 
U2OS cells, seeded at a density of 1.25x105 cells per well in a 24-well plate 
were infected with wtKSHV and harvested at the indicated time post-
infection (p.i.). Whole cell lysates were analysed by immunoblot for the 





preliminary data and more careful investigation will be conducted to further asses the 








Figure 15. RTA is co-immunoprecipitated with Prox1.  
iSLK.219 cells transduced with Prox1 pSIN WT or MUT and reactivated 
with Dox for 24h were subjected to immunoprecipitation by anti-MYC 
or control IgG and analysed by immunoblotting with the indicated 
antibodies. Actin was used as a loading control. Red arrow highlights the 






Oncogenic viruses, such as KSHV, provide unique experimental models to investigate 
the molecular biology of tumorigenesis. Oncovirology has been of immense importance 
in the discovery of tumor suppressor genes and oncogenes, and to our understanding of 
their critical role in cancer development and progression (Vogt 2012; Chang, Moore, and 
Weiss 2017). The careful study of KSHV oncogenes elucidates their role in the lifecycle 
of KSHV and capacity to induce cell transformation via interaction with the host-
signaling pathways, such as Prox1. 
In vitro, the expression of Prox1 is altered upon KSHV infection of ECs (Hong et 
al. 2004; Wang, Trotter, et al. 2004). KSHV-mediated regulation of Prox1 is a crucial 
step in the EC fate reprogramming, enabling endothelial lineages to acquire mixed 
identity resembling that of SCs of advanced KS lesions (Yoo et al. 2012). Both viral genes 
and host signaling pathways have been shown to take part in the regulation of Prox1 in 
the infected ECs (Emuss et al. 2009; Yoo et al. 2010; Cheng et al. 2011; Yoo et al. 2012; 
Chang and Ganem 2013). However, more detailed host-virus interactions contributing to 
the Prox1 expression changes need to be investigated, in addition to the underlying 
motive of this manipulation. 
Viral transcriptome analysis has revealed KSHV-infected LEC to displays 
dysregulated expression of numerous lytic cycle genes, indicating spontaneous 
reactivation in the context of continued cell survival and proliferation (Chang and Ganem 
2013). This study explores the contribution of Prox1 ectopic expression to KSHV lytic 
reactivation and stems out from our preliminary data on KSHV-infected LECs depleted 
of Prox1 which displayed a reduced spontaneous lytic reactivation. Until now, the role of 
Prox1 ectopic expression in reactivation of KSHV had not been defined. We are the first 
ones to show that Prox1 positively regulates KSHV reactivation by enhancing lytic gene 
and protein expression as well as increasing the release of infectious progeny (Figure 16). 
The promoting role of Prox1 in the RTA-dependent reactivation and transcription of 















6.1 KSHV and Prox1 manipulation – beyond EC reprogramming 
Endothelial reprogramming is a key factor in KS pathogenesis resulting in characteristic 
spindle cell. Yet it has been pondered why KSHV induces cell fate reprogramming of its 
host, whether it is a mere by-product or the goal of the viral infection, providing 
pathological advantage to KS tumorigenesis, is not known. Considering that viruses are 
dependent on their hosts to survive and reproduce, most likely it is not the goal of the 
virus to kill its host by KS manifestation. Loss of balance between the virus and the host 
has been shown to occur upon immunodeficiency in addition to virus-host interactions, 
promoting pathological oncogenesis. 
Basal, low expression of Prox1 in mature BECs is upregulated after infection, and the 
normally high level of Prox1 expression in mature LECs is downregulated after infection 
(Hong et al. 2004; Wang, Trotter, et al. 2004). It has been shown that BECs are not 
competent host for the virus. In the light of our results, one could hypothesize that Prox1 
is needed to enhance the reactivation and to maintain the population of latently infected 
cells. In infected LECs, however, Prox1 is downregulated after the acute infection 
possibly to restrict excessive reactivation and to facilitate the establishment of latency. 
As the results of this thesis demonstrate Prox1 to enhance KSHV reactivation in other 
cells than ECs, the virus might manipulate Prox1 expression in order to ensure adequate 
Figure 16. Prox1 is a positive regulator of KSHV lytic cycle. iSLK cells infected 
with rKSHV.219 express GFP in latency and RFP upon reactivation (Vieira and 
O'Hearn 2004). In this study, upon reactivation with Dox, iSLK.219 cells transduced 
with Prox1 demonstrate increased reactivation rate, lytic gene and protein expression 





levels of lytic reactivation rather than induce a specific differentiation state in the cells. 
In the midst of finding the right balance of Prox1 for viral replication, the expression 
changes in infected ECs could cause ECs to be reprogrammed towards the pathogenic SC 
type with tumorigenic abilities. Thus, the reprogramming of LECs resulting from the 
manipulation of Prox1 by KSHV may be just a side effect. 
On the other hand, KSHV induces reprogramming of LECs towards a mesenchymal 
phenotype via endothelial-to-mesenchymal transition (EndMT), endowing LECs with 
invasive properties by inducing MMP-14 upregulation (Cheng et al. 2011). vFLIP and 
vGPCR were shown to initiate the EndMT of KSHV-infected LECs through activation 
of the Notch pathway. EndMT enables cells to detach from the organised EC layer and 
acquire invasive and migratory properties (Potenta, Zeisberg, and Kalluri 2008), whereas 
MMP-14 is a key regulator of tumor cell growth and dissemination (Rowe and Weiss 
2009). The gain of MMP-14 dependent invasive properties enhance the oncogenic 
potential of infected LECs, referring to deliberative reprogramming towards thriving, 
however pathogenic cell type. Moreover, our recent studies have revealed Prox1 to 
negatively regulate MMP14 levels by binding to the MMP-14 promoter and repressing 
its transcription (Gramolelli S. manuscript in revision). Depletion of Prox1 in vivo 
increased MMP-14 expression in murine and in human LECs, promoting invasiveness 
seen as increased endothelial sprouting in a 3D invasion assay.  
Taken together, after the primary KSHV infection or reactivation from latency in 
already infected cells, Prox1 might be first upregulated to act as positive regulator of lytic 
replication, and later downregulated to facilitate the establishment of latency, and in the 
process the virus potentially induces LEC reprogramming and acquisition of oncogenic 
properties.  
 
6.2 Prox1 and KSHV - a possible dual effect on reactivation 
Being a transcription factor, Prox1 regulates the expression of other genes via binding to 
DNA. Prox1 can act both as a repressor and an enhancer of gene expression (Elsir et al. 




reprogramming. Upon KSHV infection Prox1 expression is upregulated in BECs and 
downregulated in LECs, sufficiently reprogramming distinct endothelial lineages to 
acquire mixed phenotype (Yoo et al. 2012). 
The results of this thesis show that Prox1 WT but not its mutant, devoid of DNA 
binding activity, could increase viral gene expression (Figure 9). These findings indicate 
that lytic promoting effect on gene transcription depends on the DNA binding ability of 
Prox1. Potentially Prox1 might bind to the promoter of lytic genes and enhance their 
expression, a conjecture remaining to be demonstrated in the future studies. However, at 
a protein level, Prox1 MUT has a positive effect on expression of lytic markers (Figure 
10) and in addition, Prox1 MUT moderately promotes virus production and release 
(Figure 13). A possible explanation for this is that Prox1 MUT can enhance lytic protein 
expression in a yet unknown DNA-binding-independent manner which remains to be 
investigated. Furthermore, in the experiments of this study Prox1 MUT expression was 
higher than Prox1 WT as Prox1 MUT is more stable resulting in a slower degradation 
compared to Prox1 WT. Might be, that besides being a transcription factor, Prox1 could 
regulate the degradation of proteins. This, however, remains to be investigated. 
After the reactivation of KSHV through the induction of RTA expression, the lytic 
replication cycle is initiated and downstream targets of RTA are expressed in a precise 
temporal cascade. Prox1 is promoting the lytic protein expression only after reactivation 
(Figure 10), whereas the more sensitive RT-qPCR detects an increase in the expression 
of the selected lytic genes already in latent cells upon ectopic Prox1 WT expression 
(Figure 9a). This may result from the spontaneous reactivation of very few cells prior 
induction or Prox1 might promote infected cells to prepare in unknown manner for the 
coming reactivation already during latency. This, however, is debatable and should not 
be interpreted as such before more careful investigation. RTA has been shown to be 
necessary for reactivation and initiation of lytic replication, indicating that Prox1 would 
need to the presence of RTA to cause the weak expression of lytic genes.  
Infection of U2OS cells with wtKSHV triggered a rapid increase of Prox1 protein 
expression peaking concurrently with RTA. Our ongoing studies have implicated Prox1 




Prox1 binds to RTA and enhances RTA to transactivate its own promoter as well as other 
KSHV lytic promoters (Figure 15). After the early peak, Prox1 expression progressively 
decreased and LANA was upregulated (Figure 14). This may imply that LANA could 
have a repressing role on Prox1, by downregulating its promoter to facilitate latency 
establishment. In addition to the repressing role on RTA (Lan et al. 2005; Chen et al. 
2001), LANA might downregulate Prox1 to suppress its promoting effect in reactivation. 
However, this remains to be demonstrated by further experimental studies. 
Taken together, this thesis shows for the first time that Prox1 is differentially 
regulated by KSHV in cell types other than LECs and BECs. Indeed, KSHV engages in 
adjusting Prox1 expression level upon infection of ECs, further suggesting a crucial role 
of Prox1 in the KSHV life cycle.  
 
6.3 Translational prospects 
The research on KSHV pathogenesis and development of KS is complicated due to the 
lack of suitable animal models and an endothelial cell transformation system. Also, in 
vitro cell culture models with cells expressing viral genes in isolation tend to give more 
dramatic phenotypes than those of KSHV itself, inviting misinterpretation. Nevertheless, 
experimental data should be interpreted in the context of the pathobiology of KSHV and 
comparison to clinical behavior of KS should be taken into consideration.  
However, an improved understanding of KSHV pathobiology endows possibilities for 
the development of potential targets for prevention and intervention of KSHV induced 
oncogenesis. Novel findings of KSHV reactivation could be exploited in targeting latent 
cells to reactivate, as latently-infected cells are insensitive to anti-herpesviral drugs 
targeting only viruses in the lytic phase, when the viral DNA is replicated (Kedes and 
Ganem 1997; Antman and Chang 2000). Elucidating the role of cellular factors 
manipulated by KSHV infection, such as Prox1, in viral reactivation and lytic replication 
could alleviate the health burden of KS and other lymphoproliferative diseases through 




7 Conclusions and future perspectives 
The regulation of Prox1 is altered during the KSHV infection and changes in the Prox1 
expression has an effect on the viral life cycle. The results of this thesis suggest that Prox1 
is a positive regulator of KSHV lytic reactivation from latency. Ectopic expression of 
Prox1 enhances the lytic replication and expression of lytic genes needed for the 
production of viral particles to be released from the infected host cell. This prompts 
further interest to elucidate the underlying mechanism of Prox1 to promote KSHV 
reactivation. Modulation of reactivation by Prox1 possibly results from its interaction 
with RTA, the KSHV-encoded transcription factor necessary and sufficient for the 
initiation of lytic replication. In the future, we will continue investigating the function of 
Prox1 and RTA in the KSHV reactivation. 
Prox1 has been shown to be altered after KSHV infection of LECs and BECs, 
however the kinetics of differential regulation of Prox1 expression in other cell lines has 
not been addressed. Results of this thesis suggest that KSHV modulates Prox1 expression 
levels in the infected cells according to its needs during the course of infection. In the 
future, the plan is to elucidate the expression modulation of Prox1 upon prolonged 
infection in more detail. We are determined to address whether the expression of Prox1 
eventually returns to the basal low level seen prior to the infection and to test this in other 
cell lines, especially in LECs. This thesis shows that Prox1 expression is downregulated 
after its strong induction during the lytic burst, however, the mechanisms and factors 
behind this remain be investigated.  
Development of KS following the KSHV infection is a complicated multistep 
process, where the virus-host interactions play a critical role in the signaling transduction, 
immune evasion and in the changes of the host cell identity to acquire tumorigenic 
abilities. Prox1, as one of these host factors, has an immense role in the life cycle of 
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